×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
上海药物研究所 [6]
上海生物化学与细胞生... [2]
西安交通大学 [1]
中南大学 [1]
复旦大学上海医学院 [1]
中国医学科学院 北京... [1]
更多...
内容类型
期刊论文 [13]
发表日期
2019 [2]
2018 [2]
2017 [2]
2016 [1]
2014 [2]
2012 [1]
更多...
学科主题
Biochemist... [1]
Cell Biolo... [1]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共13条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met
期刊论文
CANCER SCIENCE, 2019, 页码: 11
作者:
Tong, Mengya
;
Gao, Mingzhao
;
Xu, Yongping
;
Fu, Li
;
Li, Yun
收藏
  |  
浏览/下载:23/0
  |  
提交时间:2020/07/01
AZD9291
c-Met ADC
c-Met overexpression
resistance
SHR-A1403
Transforming growth factor beta signaling pathway: A promising therapeutic target for cancer
期刊论文
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 页码: 12
作者:
Yang, Hongying
;
Zhang, Hong
;
Zhang, Qianjing
;
Zhang, Jinhua
;
Xu, Caipeng
收藏
  |  
浏览/下载:66/0
  |  
提交时间:2019/11/10
clinical application
drug
inhibitors
TGF-beta
tumor
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor
期刊论文
CANCER SCIENCE, 2018, 卷号: 109, 期号: 4, 页码: 1207-1219
作者:
Xie, Chengying
;
Wan, Xiaozhe
;
Quan, Haitian
;
Zheng, Mingyue
;
Fu, Li
收藏
  |  
浏览/下载:45/0
  |  
提交时间:2019/01/08
angiogenesis
anlotinib
tyrosine kinase inhibitor
VEGF
VEGFR2
Broad targeting of triptolide to resistance and sensitization for cancer therapy
期刊论文
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, 卷号: 104, 页码: 771-780
作者:
Hou, Zhen-yan
;
Tong, Xiao-pei
;
Peng, Yong-bo
;
Zhang, Bi-Kui*
;
Yan, Miao*
收藏
  |  
浏览/下载:50/0
  |  
提交时间:2019/12/03
ABC
ATP-binding cassette
AKT
V-Akt murine thymoma viral oncogene homolog
ALDH1
aldehyde dehydrogenase 1
AR
androgen receptor
Bad
Bcl-2-associated death promoter
Bak
Bcl-2 homologous antagonist killer
Bax
Bcl-2-associated X protein
Bcl-2
B-cell lymphoma
Bcl-xL
Bcl-extra large
Bcl-xs
Bcl-extra short
BCRP
breast cancer resistance protein
Bid
BH3 interacting domain death agonist
Bik
Bcl-2-interacting killer
BNIP3
Bcl2/adenovirus E1B 19 kDa protein-interacting protein 3
CAF
cancer-associated fibroblast
CAIX
carbonic anhydrase IX
cFLIP
cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein
ChIP
chromatin immunoprecipitation
CI
Combination Index
cIAP1/2
cellular IAP1/2
CML
chronic myelogenous leukemia
CSC
cancer stem cell
DISC
death-inducing signaling complex
DR
death receptor
DRI
Dose Reduction Index
ECM
extracellular matrix
EMT
epithelial-mesenchymal transition
EpCAM
epithelial cell adhesion molecule
GLUT
glucose transporter
GSK3β
glycogen synthase kinase-3β
HIF-1
hypoxia inducible factor-1
HSF1
heat shock factor 1
HSP
heat shock protein
IAP
inhibitor of apoptosis protein
JNK
c-JUN N-terminal kinase
MAPK
mitogen-activated protein kinase
Mcl-1
myeloid leukemia cell differentiation protein
MDM2
murine double minute 2
MDR
multidrug resistance
MKP
MAPK phosphatase
MRP1
multidrug resistance protein 1
NF-κB
nuclear factor-kappaB
pAkt
phosphor-Akt
PARP
poly ADP-ribose polymerase
P-gp
P-glycoprotein
PI3K-PTEN
phosphatidylinositol 3-kinase-phosphatase and tensin homolog
PKC
phosphorylated at Ser9 by protein kinase C
pp2A
protein phosphatase 2A
REST
repressor element-1 silencing transcription factor
SAR
structure-activity relationship
TAM
tumor-associated macrophage
TFIIH
transcription factor IIH
TKI
tyrosine kinase inhibitor
TM
tumor-microenvironment
TRAIL/Apo-2L
TNF-related apoptosis-inducing ligand
tRXRα
the N-terminal truncated form of the nuclear retinoid X receptor-α
TWHF
Tripterygium wilfordii Hook F
VEGF
vascular endothelial growth factor
XIAP
X-linked IAP
XPB
xerodermapigmentosum group B protein
Triptolide
Antineoplastic
Resistance
Sensitization
Mechanism
Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report
期刊论文
ONCOLOGY LETTERS, 2017, 卷号: 14, 期号: 1
作者:
Fang, Liying
;
He, Jian
;
Xia, Jingwen
;
Dong, Liang
;
Zhang, Xiujuan
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2019/12/05
epithelial growth factor receptor tyrosine kinase inhibitor
lung adenocarcinoma
small cell lung cancer
resistance
A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition.
期刊论文
Respiratory medicine case reports, 2017, 卷号: 22, 页码: 183-186
作者:
Zhang Nana
;
Wang Depu
;
Li Xiaofeng
;
Yang Zhe
;
Zhang Guanjun
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2019/11/26
EGFR-TKI resistance
Epidermal growth factor receptor tyrosine kinase inhibitor
Epithelial-to-mesenchymal transition
Secondary mutation
Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors
期刊论文
BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 卷号: 24, 期号: 12, 页码: 2673-2680
作者:
Xiao, Qiang
;
Qu, Rong
;
Gao, Dingding
;
Yan, Qi
;
Tong, Linjiang
收藏
  |  
浏览/下载:23/0
  |  
提交时间:2019/01/08
5-(Methylthio)pyrimidine derivatives
Mutant selective inhibitors
Epidermal growth factor inhibitor
NSCLC
Structure-based drug design
SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo
期刊论文
CANCER LETTERS, 2014, 卷号: 351, 期号: 1, 页码: 143-150
作者:
Wang, Lu
;
Ai, Jing
;
Shen, Yanyan
;
Zhang, Haotian
;
Peng, Xia
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2019/01/08
c-Met
SOMCL-863
Receptor tyrosine kinase
Cancer
Angiogenesis
Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells
期刊论文
ACTA PHARMACOLOGICA SINICA, 2014, 卷号: 35, 期号: 1, 页码: 89-97
作者:
He, Chang-xi
;
Ai, Jing
;
Xing, Wei-qiang
;
Chen, Yi
;
Zhang, Hao-tian
收藏
  |  
浏览/下载:76/0
  |  
提交时间:2019/01/08
human cancer
anticancer drug
Yhhu3813
c-Met
receptor tyrosine kinase
xenograft nude mouse model
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer
期刊论文
2012, 卷号: 36, 期号: 5, 页码: 490-496
作者:
Gui, Ting
;
Shen, Keng
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2020/01/13
Epidermal growth factor receptor (EGFR)
Epithelial ovarian cancer (EOC)
Monoclonal antibody (MAb)
Tyrosine kinase inhibitor (TKI)
Resistance
©版权所有 ©2017 CSpace - Powered by
CSpace